Trastuzumab deruxtecan in patients with central nervous system involvement from HER2-positive breast cancer: The DEBBRAH trial
José Manuel Pérez-García(MedSIR (Spain)), Sofía Braga(Hospital Prof. Dr. Fernando Fonseca), Patricia Cortez(Hospital Ruber Internacional), Laia Garrigós(Hospital Universitario Dexeus), Antonio Llombart‐Cussac(MedSIR (Spain)), María Gión(Hospital Universitario Ramón y Cajal), Juan de la Haba-Rodríguez(Instituto Maimónides de Investigación Biomédica de Córdoba), Manuel Ruíz‐Borrego(Hospital Universitario Virgen del Rocío), Javier Cortés(Villa Maria Hospital), Marta Vaz Batista(Hospital Prof. Dr. Fernando Fonseca), Sonia Servitja(Hospital Del Mar), Andrea Malfettone(MedSIR (Spain)), Alejandro Martínez‐Bueno(Hospital Universitario Dexeus), Mónica Nave(Hospital da Luz), Miguel Sampayo-Cordero(MedSIR (Spain)), María Fernández(Hospital Universitario Ramón y Cajal), Juan Miguel Cejalvo(Universitat de València), Salvador Blanch(Hospital Prof. Dr. Fernando Fonseca), Fabricio Racca(Instituto Oncológico Dr. Rosell)
Cited by 247
Related Papers
Pembrolizumab for Early Triple-Negative Breast Cancer
|New England Journal of Medicine|2020|3.1k
Breast cancer
|Nature Reviews Disease Primers|2019|2.9k
MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2− Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy
|Journal of Clinical Oncology|2017|1.7k
ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer
|Annals of Oncology|2021|1.4k